Abstract
Background Initiation of disease-modifying therapy early in the disease course of relapsing-remitting multiple sclerosis (RRMS) has demonstrated beneficial effects on clinical outcomes, but socioeconomic outcomes remain largely unexplored.Objective To investigate...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have